Press Releases

Date Title and Summary Additional Formats
Toggle Summary FDA Exempts Evoke from Requirement for Human Factor Validation Study
Company reaffirms NDA submission by year end 2017
View HTML
Toggle Summary GIMOTI Receives Nomination for 2022 Healio Industry Breakthrough Award
GIMOTI recognized as a major disruptor in the gastroenterology field, including several large global pharmaceutical companies Vote for GIMOTI as 2022 Healio Industry Breakthrough Product via Survey SOLANA BEACH, Calif. , Sept. 14, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML
Toggle Summary GIMOTI® Commercialization Update
New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com   Expanded Coverage with recent New York Medicaid Approval SOLANA BEACH, Calif. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma ,
View HTML
Toggle Summary New GIMOTI Patent Listed in FDA Orange Book
Broad Formulation Patent Expands Protection for Gimoti SOLANA BEACH, Calif. , May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK),  a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®  (metoclopramide)
View HTML
Toggle Summary Patient Experience Survey Reported Positive Findings for GIMOTI®
Research Study Among Patients Demonstrated Favorable Acceptance and Utilization of GIMOTI SOLANA BEACH, Calif. and CHICAGO , May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and
View HTML
Toggle Summary Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA
SOLANA BEACH, Calif., April 04, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company recently completed a positive Type A meeting with the U.S.
View HTML
Toggle Summary Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported
Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide Supports Safety Profile of Only Approved Molecule in US to Treat Symptoms of Acute and Recurrent Diabetic
View HTML
Toggle Summary Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources
Patients treated with Gimoti® (metoclopramide) nasal spray showed statistically significant fewer emergency department visits, inpatient hospitalizations, and physician office visits than patients who were treated with oral metoclopramide SOLANA BEACH, Calif.
View HTML
Toggle Summary U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001
States Patients With Diabetic Gastroparesis May Have Unpredictable Gastric Emptying and Altered Absorption of Orally-Administered Hypoglycemic Drugs
View HTML
Toggle Summary United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
The Company Will Submit for FDA Orange-Book Listing in the Near Term SOLANA BEACH, Calif. , Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®
View HTML